Pharminent

FDA approves Bayer’s Sunharbo for secondary stroke prevention

The FDA approved Bayer’s asundexian, branded Sunharbo, a once-daily pill, for secondary stroke prevention in adults. The source reports it is the first FDA-approved drug in a new class of cardiovascular medicines.

FDA approves Merck’s Pimjetmi for tenosynovial giant cell tumor

Merck’s Pimjetmi was cleared in the US for tenosynovial giant cell tumor, making it the third FDA-approved treatment for the rare disorder.

Beam’s base editing sickle cell therapy meets pivotal trial goal

Beam’s base editing therapy risto-cel met its goal in a pivotal trial in sickle cell disease. The company could submit an FDA application as soon as the end of the year.

PepGen shares jump on early myotonic dystrophy data

PepGen reported early results from a small study of its therapy for myotonic dystrophy type 1, and its shares rose on the findings.

Levicept presents new LEVI-04 osteoarthritis data at ACR

Levicept reported new data on LEVI-04 in patients with osteoarthritis at ACR, which the company says support its potential to become the first new systemic treatment for the condition in more than two decades.

AstraZeneca acquires vaccine developer Omniose

AstraZeneca has acquired Omniose, a US biotech developing polysaccharide conjugate vaccines for bacterial infections, following a three-year partnership between the two companies.

ProBio licenses early-stage antibody from AbTis worldwide

ProBio entered an exclusive worldwide licensing agreement with South Korean biotech AbTis to develop and commercialize an early-stage therapeutic antibody asset.

Children’s Tumor Foundation takes equity stake in GondolaBio program

The Children’s Tumor Foundation is providing clinical expertise and scientific infrastructure, rather than cash, in exchange for an equity stake in GondolaBio’s preclinical NF1 drug program.

Oyster Therapeutics raises $60M for protein degraders

Oyster Therapeutics closed a $60 million Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.

Pfizer names Cecile Guegan chief financial officer

Cecile Guegan has become Pfizer’s chief financial officer, the company’s first permanent female CFO.

Democrats move toward probe of MFN drug pricing deals

Incoming Democratic chairs of key congressional committees have taken a step toward investigating most-favored-nation drug pricing agreements struck between drugmakers and the Trump administration, sending letters to manufacturers.